Figure 8.

The mechanism of DoMRE against hyperuricemia. The yellow arrow represents hyperuricemia, whereas the green arrow represents DoMRE. On the one hand, DoMRE significantly upregulates the expressions of intestinal ZO-1 and occludin proteins, and reduce the intestinal barrier function damage caused by inflammatory factors, which cause the villus height significantly increased of intestinal tissue and a significant decrease in crypt depth of ileum, all of which lead to the improvement of the intestinal barrier function and the assurance of the normal function of intestinal UA excretion. Besides, the DoMRE treatment upregulate the expression of ABCG2 and downregulate the expression of GLUT9 to promote the intestinal UA excretion and purine intaking, ultimately reducing the SUA level. Besides, the DoMRE treatment upregulate the expressions of intestinal ZO-1 and claudin-1 proteins, to improve the intestinal barrier function, so as to ensure the normal function of intestinal UA excretion. Meanwhile, DoMRE can also inhibit XOD and ADA activity in intestine and liver to a certain extent, which ultimately lead to the reduction of the SUA level.